Onkológia 6/2010
PARP inhibitors
Triple negative breast cancer (TNBC) is defined as tumor that is negative for estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor (HER2). There is no targeted therapy for this tumor subtype yet. PARP – poly(ADP-ribose)polymerase-1 is an key enzyme involved in DNA repair, is esential for the repair of DNA single strand break (SSB). Promising novel class of anticancer agents – PARP inhibitors are emerging as very effective drugs in TNBC therapy.
Keywords: Triple-negatívny breast cancer (TNBC), basal-like breast cancer (BLBC), BRCA, targeted therapy.
